|
Objective: To observe the clinical efficacy and adverse effects of berberine lipid-lowering agent in patients with hyperlipidemia, objective evaluation of the efficacy and safety of the treatment, in order to explore a safe, reliable, and suitable for the promotion of traditional Chinese medicine treatment of hyperlipidemia preparation and preliminary study of its mechanism of action, provide the basis for the clinical treatment of hyperlipidemia. Methods: 60 cases were selected from July 2008 to January 2010 in Wuhan City, a hospital inpatient department of cardiovascular medicine two wards and outpatient cases, patients who meet the diagnostic criteria of hyperlipidemia. Were randomly divided into two groups, the treatment group and the control group, the treatment group, 32 cases in the control group of 28 cases. Both groups were asked the low-salt, low-fat diet. The group was treated with berberine lipid-lowering agents and with symptomatic treatment and control group were treated with fluvastatin capsules with symptomatic treatment. Treatment for two months. Recorded once before and after treatment in patients with serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), high density lipoprotein (HDL), C-reactive protein (CRP), atherosclerosis hardening exponent ( AI) values, electrocardiogram (ECG). Lipid levels before and after treatment were compared. Made Efficacy of in accordance with the appropriate diagnostic criteria. General physical examination of the two groups were observed before and after treatment projects, such as temperature (T), pulse (P), respiration (R), blood pressure (BP), blood, urine, stool, heart function, liver function, renal function , electrolyte analysis, ECG and adverse reactions. And make safety evaluation. After the end of the clinical observation, all the data for statistical analysis. Variable data as mean ± standard deviation (x ± s) for statistical description, measurement data using t test, count data using the x2 test. P gt; 0.05 means that no significant difference, P lt; 0.05 that the results were significantly different, P lt; 0.01 indicates statistical significant difference. Results: (1) two clinical efficiency comparison: the treatment group was 96.88%, the control group was 96.43%, two clinical efficiency was no significant difference (P GT; 0.05) Comparison of the 2 groups of patients serum TG, TC, LDL, HDL, CRP, AI values: group comparison: two groups after treatment than before treatment serum TC, LDL, CRP, AI reduced, elevated serum HDL values, statistics analysis of significant differences (P lt; 0.05), and serum TG value no significant change (P gt; 0.05); between the two groups: treatment group and the control group before treatment comparison, serum TC, LDL, CRP, AI, TG value There was no significant difference (P gt; 0.05); the control group and the treatment group after treatment, serum TC, LDL, CRP, AI, TG value was no significant difference (P gt; 0.05) (3) compare the treatment of the two groups before and after treatment ECG before the two groups ECG showed ST-segment depression, calculated before and after the treatment of patients with ST-segment depression ST-segment depression sum (ΣST). Between the two groups: two groups before treatment ΣST no significant difference (P gt; 0.05); the ΣST After treatment showed no significant difference (P GT; 0.05); compare group comparison: Before treatment After treatment There are significant differences (P lt; 0.05) safety testing: two groups of patients before and after treatment serum for detection of toxic side effects, the treatment process, after treatment were not found adverse reactions and side effects. Conclusion: Clinical observations suggest that: Coptis lipid-lowering agent in patients with hypercholesterolemia have a good effect. Can significantly reduce serum TC, LDL, CRP, AI value can increase serum HDL values, no significant change in the TG, its efficacy, good safety performance, non-toxic side effects.
|